The key objectives of the CRM regulations include the following:
- Facilitate access to CRM
- To require imported or locally-manufactured CRM to be of sufficient quality
- To restrict the supply of imported or locally-manufactured CRM to regulated clinical trials or IRB-approved clinical research
- To require traceability and accountability of CRM through record-keeping
- To require appropriate CRM labelling
- To require reporting of unexpected serious adverse drug reactions (USADRs), or medical device adverse events related to the use of CRM
- To require disposal/export of imported or locally-manufactured CRM after
the research/trial ends